BACKGROUND: Despite recent progress in the treatment of advanced urothelial cancer, there continues to be a need to identify new active agents and their toxicity spectra. We conducted a study using FOLFOX-4 (oxaliplatin, fluorouracil, folinic acid) in pre-treated advanced bladder cancer patients. METHODS: Sixteen eligible patients with advanced disease were treated with oxaliplatin (85 mg/m(3)) on day 1 followed by fluorouracil and folinic acid (De Gramont schedule) on days 1 and 2 every 14 days until disease progression. All patients received nutritional support to increase their caloric intake. Objective responses and toxicity were evaluated. Biochemical responses (reduction of markers) and nutritional parameters (increase in body weight and albumin, and reduction in ferritin and C-reactive protein) were also considered. RESULTS: Three patients obtained an objective response (overall response rate 19\%). Hematological toxicity and stomatitis were the most commonly noted side effects, but we observed only low (3-4) grade toxicity. In four patients (25\%), we observed a reduction in tumoral markers (carcinoembryonic antigen and tissutal polypeptide antigen) and modified nutritional parameters. CONCLUSIONS: Using these doses and schedules of FOLFOX-4 appears to be a promising therapy in patients pre-treated with platinum compounds. More studies are required to assess the possible role of this regimen in the treatment of advanced bladder cancer.

FOLFOX-4 in pre-treated patients with advanced transitional cell carcinoma of the bladder / Giuseppe Di, Lorenzo; Riccardo, Autorino; Antonio, Giordano; Giuliano, Mario; Massimo, D'Armiento; Bianco, ANGELO RAFFAELE; DE PLACIDO, Sabino. - In: JAPANESE JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0368-2811. - STAMPA. - 34:(2004), pp. 747-750.

FOLFOX-4 in pre-treated patients with advanced transitional cell carcinoma of the bladder.

GIULIANO, MARIO;BIANCO, ANGELO RAFFAELE;DE PLACIDO, SABINO
2004

Abstract

BACKGROUND: Despite recent progress in the treatment of advanced urothelial cancer, there continues to be a need to identify new active agents and their toxicity spectra. We conducted a study using FOLFOX-4 (oxaliplatin, fluorouracil, folinic acid) in pre-treated advanced bladder cancer patients. METHODS: Sixteen eligible patients with advanced disease were treated with oxaliplatin (85 mg/m(3)) on day 1 followed by fluorouracil and folinic acid (De Gramont schedule) on days 1 and 2 every 14 days until disease progression. All patients received nutritional support to increase their caloric intake. Objective responses and toxicity were evaluated. Biochemical responses (reduction of markers) and nutritional parameters (increase in body weight and albumin, and reduction in ferritin and C-reactive protein) were also considered. RESULTS: Three patients obtained an objective response (overall response rate 19\%). Hematological toxicity and stomatitis were the most commonly noted side effects, but we observed only low (3-4) grade toxicity. In four patients (25\%), we observed a reduction in tumoral markers (carcinoembryonic antigen and tissutal polypeptide antigen) and modified nutritional parameters. CONCLUSIONS: Using these doses and schedules of FOLFOX-4 appears to be a promising therapy in patients pre-treated with platinum compounds. More studies are required to assess the possible role of this regimen in the treatment of advanced bladder cancer.
2004
FOLFOX-4 in pre-treated patients with advanced transitional cell carcinoma of the bladder / Giuseppe Di, Lorenzo; Riccardo, Autorino; Antonio, Giordano; Giuliano, Mario; Massimo, D'Armiento; Bianco, ANGELO RAFFAELE; DE PLACIDO, Sabino. - In: JAPANESE JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0368-2811. - STAMPA. - 34:(2004), pp. 747-750.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/338105
Citazioni
  • ???jsp.display-item.citation.pmc??? 7
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact